drugset / Trial / NCT07473726
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX48 in patients with advanced/metastatic solid tumors.
Timeline
- Start
- 2026-06-30
- Primary completion
- 2027-03
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX48 | Unknown | — | Intravenous |
Indications
No indication recorded.